143 related articles for article (PubMed ID: 6099688)
1. Brain neurotransmitters and neuropeptides in Parkinson's disease.
Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P
Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688
[TBL] [Abstract][Full Text] [Related]
2. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
Rinne UK; Rinne JO; Rinne JK; Laakso K; Laihinen A; Lönnberg P
J Neural Transm Suppl; 1983; 18():279-86. PubMed ID: 6308149
[TBL] [Abstract][Full Text] [Related]
3. Chemical neurotransmission in the parkinsonian brain.
Rinne UK; Rinne JO; Rinne JK; Laakso K
Med Biol; 1987; 65(2-3):75-81. PubMed ID: 2821331
[TBL] [Abstract][Full Text] [Related]
4. Brain enkephalin receptors in Parkinson's disease.
Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
[TBL] [Abstract][Full Text] [Related]
5. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
Mogi M; Kondo T; Mizuno Y; Nagatsu T
Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
[TBL] [Abstract][Full Text] [Related]
6. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
[TBL] [Abstract][Full Text] [Related]
7. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
Anglade P; Tsuji S; Javoy-Agid F; Agid Y; Hirsch EC
Ann Neurol; 1995 Feb; 37(2):265-72. PubMed ID: 7847868
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
Ruberg M; Javoy-Agid F; Hirsch E; Scatton B; LHeureux R; Hauw JJ; Duyckaerts C; Gray F; Morel-Maroger A; Rascol A
Ann Neurol; 1985 Nov; 18(5):523-9. PubMed ID: 3000280
[TBL] [Abstract][Full Text] [Related]
9. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R; Greenamyre JT
Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
[TBL] [Abstract][Full Text] [Related]
10. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Calabresi P; Mercuri NB; Sancesario G; Bernardi G
Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
[TBL] [Abstract][Full Text] [Related]
12. Studies on aging processes.
Agnati LF; Fuxe K; Benfenati F; Toffano G; Cimino M; Battistini N; Calza L; Merlo Pich E
Acta Physiol Scand Suppl; 1984; 532():45-61. PubMed ID: 6093434
[TBL] [Abstract][Full Text] [Related]
13. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease.
Anichtchik OV; Peitsaro N; Rinne JO; Kalimo H; Panula P
Neurobiol Dis; 2001 Aug; 8(4):707-16. PubMed ID: 11493035
[TBL] [Abstract][Full Text] [Related]
14. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
15. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease as a model for changes in dopamine receptor dynamics with aging.
Rinne UK
Gerontology; 1982; 28 Suppl 1():35-52. PubMed ID: 7044903
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
18. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
Elsworth JD; Roth RH
Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
[TBL] [Abstract][Full Text] [Related]
19. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.
Ahlskog JE; Richelson E; Nelson A; Kelly PJ; Okazaki H; Tyce GM; van Heerden JA; Stoddard SL; Carmichael SW
Ann Neurol; 1991 Aug; 30(2):185-91. PubMed ID: 1654766
[TBL] [Abstract][Full Text] [Related]
20. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
